Raymond James analyst Danielle Brill resumed coverage of Regenxbio with an Outperform rating and $45 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RGNX:
- Biotech Alert: Searches spiking for these stocks today
- Regenxbio to hold a conference call
- Regenxbio says CAMPSIITE trial of RGX-121 achieves primary endpoint
- Regenxbio provides update from Phase I/II AFFINITY DUCHENNE trial of RGX-202
- Regenxbio reports ‘positive’ interim data from AAVIATE trial
Questions or Comments about the article? Write to editor@tipranks.com